Zeltia Group’s Yondelis Approved in Russia for Sarcoma

November 25, 2008 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

MADRID, Nov 25 (Reuters) - Spanish biotech company Zeltia said on Tuesday that its partner Ortho Biotech Products has won approval to market its Yondelis cancer drug in Russia for the treatment of soft tissue sarcoma (STS) in adults.

Twitter
LinkedIn
Facebook
Email
Print

FDA Approvals Europe